Literature DB >> 10465404

Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors.

M Legraverend1, O Ludwig, E Bisagni, S Leclerc, L Meijer, N Giocanti, R Sadri, V Favaudon.   

Abstract

Novel C-2, C-6, N-9 trisubstituted purines derived from the olomoucine/roscovitine lead structure were synthesized and evaluated for their ability to inhibit starfish oocyte CDK1/cyclin B, neuronal CDK5/p35 and erk1 kinases in purified extracts. Structure activity relationship studies showed that increased steric bulk at N-9 reduces the inhibitory potential whereas substitution of the aminoethanol C-2 side chain by various groups of different size (methyl, propyl, butyl, phenyl, benzyl) only slightly decreases the activity when compared to (R)-roscovitine. Optimal inhibitory activity against CDK5, CDK1 and CDK2, with IC50 values of 0.16, 0.45 and 0.65 microM, respectively, was obtained with compound 21 containing a (2R)-pyrrolidin-2-yl-methanol substituent at the C-2 and a 3-iodobenzylamino group at the C-6 of the purine. Compound 21 proved cytotoxic against human tumor HeLa cells (LD50-6.7 microM versus 42.7 microM for olomoucine, 24-h contact). Furthermore, unlike olomoucine, compound 21 was effective upon short exposure (LD50= 25.3 microM, 2-h contact). The available data suggest that the affinity for CDKs and the cytotoxic potential of the drugs are inter-related. However, no straightforward cell cycle phase specificity of the cytotoxic response to 21 was observed in synchronized HeLa cells. With the noticeable exception of pronounced lengthening of the S-phase transit by 21 applied during early-S in synchronized HeLa cells, and in striking contrast with earlier reports on studies using plant or echinoderm cells. olomoucilnc and compound 21 were unable to reversibly arrest cell cycle progression in asynchronous growing HeLa cells. Some irreversible hlock in GI and G2 phase occurred at high olomoucine concentration, correlated with induced cell death. Moreover, chmronic exposure to lethal doses of compound 21 resulted in massive nuclear fragmentation, evocative of mitotic catastrophe with minour amounts of apoptosis only. It was also found that olomoucine and compound 21 reversibly block the intracellular uptake of nuicleosides with high efficiency.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10465404     DOI: 10.1016/s0968-0896(99)00064-4

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  6 in total

Review 1.  The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.

Authors:  Katrien Vermeulen; Dirk R Van Bockstaele; Zwi N Berneman
Journal:  Cell Prolif       Date:  2003-06       Impact factor: 6.831

2.  Diverse effects of the cyclin-dependent kinase inhibitor bohemine: Concentration- and time-dependent suppression or stimulation of hybridoma culture.

Authors:  F Franek; M Strnad; L Havlícek; V Siglerová; I Fismolová; T Eckschlager
Journal:  Cytotechnology       Date:  2001-07       Impact factor: 2.058

3.  Structure-based design of potent CDK1 inhibitors derived from olomoucine.

Authors:  P Furet; J Zimmermann; H G Capraro; T Meyer; P Imbach
Journal:  J Comput Aided Mol Des       Date:  2000-07       Impact factor: 3.686

4.  8-Amino-adenosine inhibits multiple mechanisms of transcription.

Authors:  Jennifer Ann Frey; Varsha Gandhi
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

5.  Several human cyclin-dependent kinase inhibitors, structurally related to roscovitine, are new anti-malarial agents.

Authors:  Sandrine Houzé; Nha-Thu Hoang; Olivier Lozach; Jacques Le Bras; Laurent Meijer; Hervé Galons; Luc Demange
Journal:  Molecules       Date:  2014-09-23       Impact factor: 4.411

6.  Synthetic Routes to N-9 Alkylated 8-Oxoguanines; Weak Inhibitors of the Human DNA Glycosylase OGG1.

Authors:  Tushar R Mahajan; Mari Eknes Ytre-Arne; Pernille Strøm-Andersen; Bjørn Dalhus; Lise-Lotte Gundersen
Journal:  Molecules       Date:  2015-09-02       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.